KR102429851B1 - Composition comprising camellia sinensis L. root extract for anti-aging or anti-inflammation - Google Patents

Abstract

Herein, as a composition comprising a tea tree root extract as an active ingredient, an anti-aging composition that regulates the expression level of XDH (NM_000379), a gene in skin cells affected by stimuli that causes inflammation or aging, to a normal level and anti-inflammatory compositions.

Description

Anti-aging or anti-inflammatory composition comprising a tea tree root extract {Composition comprising camellia sinensis L. root extract for anti-aging or anti-inflammation}

Disclosed herein are anti-aging and anti-inflammatory compositions. More specifically, compared to normal skin cells, the biomarker, which is a skin cell gene whose expression level is changed by aging and inflammation, is significantly changed to reduce aging and inflammation of skin cells. A composition is disclosed.

As in these days, artificial temperature control of cooling/heating according to changes in the environment or life patterns, skin stress due to various stresses and environmental pollution occurring in social life, frequent washing due to makeup habits, and natural skin due to increasing age Inflammation and skin aging are occurring.

In addition, excessive physical and chemical stimuli, ultraviolet rays and stress from the outside reduce the normal function of the skin and promote phenomena such as loss of elasticity, keratinization, wrinkle formation, and inflammation. It is becoming a source of irritation, a source of aging, or a source of inflammation.

Currently, various skin diseases caused by fine dust are being studied, but there are not many natural extracts that have been shown to be effective in alleviating such skin damage.

It is currently known that XDH represents oxidative stress induced by prolonged exposure to an irritant, and as a result is an indicator of extrinsic skin aging (see Non-Patent Document 1).

Kim, H.J., et al, "Transcriptome analysis of airborne PM2.5-induced detrimental effects on human keratinocytes", Toxicology Letters 273, 26-35, 2017.

Accordingly, the present inventors have determined that the irritant causing inflammation or aging has a detrimental effect on the skin, and by this effect, symptoms such as skin cell aging and inflammation appear by affecting the expression of skin cell genes. The composition according to the present invention found to have anti-aging and anti-inflammatory properties.

Accordingly, in one aspect, the present invention aims to provide an anti-aging composition and an anti-inflammatory composition.

In order to achieve the above object, in one aspect, the present invention provides a composition comprising a tea tree root extract as an active ingredient, XDH (NM_000379), which is a gene in skin cells whose expression level is affected by stimulants that cause inflammation or aging It provides an anti-aging composition and an anti-inflammatory composition for regulating the expression level to a normal level.

In one aspect, by using the anti-aging composition and the anti-inflammatory composition provided by the present invention, it is possible to reduce the damage to skin cells by returning the gene expression level changed by inflammation or aging stimulation to a normal level.

1 shows the cell viability by treatment with an irritant, where ADSP represents yellow dust as Asian dust storm particles, and PM10 (Particulate matter 10) represents fine dust with a particle size of 10 μm. , PM2.5 (Particulate matter 2.5) represents fine dust with a particle size of 2.5㎛.
FIG. 2 shows that the mRNA expression level of the XDH gene was increased in skin cells subjected to inflammation or aging stimuli, and returned to a normal level by treatment with a tea tree root extract.
In the drawings, "Nokpu 1" is 1 ppm of tea root ethanol extract (Example 1), "Nokpu 5" is 5 ppm of tea root ethanol extract (Example 1), and "Noxa 1" is 1 ppm of the butanol fraction of the tea root ethanol extract (Example 2) was treated (Example 2), "Noxa 5" was treated with 5 ppm of the butanol fraction of the tea root ethanol extract (Example 2), and "NT" was treated with fine dust Without, “cont1” and “cont2” refer to the respective controls.

Hereinafter, the present invention will be described in detail.

In one aspect of the present invention, the composition may include a tea tree root extract as an active ingredient.

Camellia sinensis is a perennial evergreen plant belonging to theaceae, distributed in tropical, subtropical, and temperate regions. The main components of tea tree include catechin, saponin, caffeine, amino acids, vitamins and minerals, It has been reported to exhibit various physiological activities and pharmacological effects. Today, active research is being conducted as a bioactive substance that contributes to health.

In one aspect, the tea tree root extract may be an extract containing saponins.

In one aspect, the tea tree root extract may contain 30 to 70% by weight of saponins based on the total weight of the extract. Preferably, the tea tree root extract may contain 50 to 60% by weight of saponins based on the total weight of the extract. When the saponin was in the above content range, the anti-aging and anti-inflammatory effects of the tea tree root extract were excellent.

Specifically, 30% by weight or more, 31% by weight or more, 32% by weight or more, 33% by weight or more, 34% by weight or more, 35% by weight or more, 36% by weight or more, 37% by weight or more, 38% by weight or more, 39% by weight or more % or more, 40% or more, 41% or more, 42% or more, 43% or more, 44% or more, 45% or more, 46% or more, 47% or more, 48% or more, 49% or more % or more, 50 wt% or more, 51 wt% or more, 52 wt% or more, 53 wt% or more, 54 wt% or more, or 55 wt% or more, and 70 wt% or less, 69 wt% or less, 68 wt% or less , 67 wt% or less, 66 wt% or less, 65 wt% or less, 64 wt% or less, 63 wt% or less, 62 wt% or less, 61 wt% or less, 60 wt% or less, 59 wt% or less, 58 wt% or less , 57 wt% or less, 56 wt% or less, or 55 wt% or less, but is not limited thereto.

In one aspect of the present invention, the tea tree root may be extracted with a specific extraction solvent to form a tea tree root extract.

According to one aspect of the present invention, the tea tree root extract may be prepared by extracting the tea tree root with water or an organic solvent, which is a primary extraction solvent. Specifically, the primary extraction solvent is water, C ₁ -C ₆ Anhydrous or hydrous lower alcohol, acetone, butylene glycol, ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform and selected from the group consisting of hexane It may be any one or more extraction solvents. More specifically, the extraction includes water, a C ₁ - C ₆ anhydrous or hydrous lower alcohol, a polar solvent including acetone and butylene glycol, and ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform and hexane. It may be to use any one or more of the low-polarity solvent as a solvent. More specifically, the solvent may be 50 - 90% ethanol aqueous solution, 60 - 80% or 65 - 75% ethanol aqueous solution. When the solvent is an aqueous solution of 50 to 90% ethanol, the active ingredient can be effectively extracted from the root of the tea tree. In one embodiment, the solvent may be about 70% ethanol aqueous solution.

In one aspect, the tea tree root extract may be prepared by extraction with the primary extraction solvent and fractionation with the secondary extraction solvent. Specifically, the secondary extraction solvent may be anhydrous or hydrous butanol. Through the fractionation, the content of a specific component included in the extract can be further increased, and specifically, the content of saponins included in the tea tree root extract can be further increased. For example, the saponin content of the extract obtained by fractionating the tea tree root extract with the secondary extraction solvent than the tea tree root extract extracted with the primary extraction solvent is, for example, 5% by weight or more, 6% by weight or more based on the weight of the total extract , 7% by weight or more, 8% by weight or more, 9% by weight or more, 10% by weight or more, 11% by weight or more, 12% by weight or more, 13% by weight or more, 14% by weight or more, or 15% by weight or more and may be further increased by 5-15% by weight.

In one embodiment, the tea tree root extract is fractionated with 70% ethanol as the primary extraction solvent and butanol as the secondary extraction solvent. For example, the saponin content of the tea tree root extract extracted using 70% ethanol as the primary extraction solvent may be about 55.8% by weight based on the total weight of the extract, and the tea tree root extract is fractionated using butanol as the secondary extraction solvent The saponin content of one extract may be about 67.6% by weight based on the total weight of the extract. Accordingly, the saponin content of the extract through the fraction can be increased by about 11.8% by weight.

In one aspect, the tea tree root extract may be obtained by additionally passing through one or more of filtration, concentration, separation or drying processes after extraction with the extraction solvent. In particular, the tea root extract may be one that has undergone one or more filtration processes.

In one aspect, the extract may be concentrated under reduced pressure at an appropriate temperature in a distillation apparatus equipped with a cooling condenser after extraction, specifically at a temperature of about 50 °C.

However, the tea root extract according to the present invention can be obtained by extraction by a conventional method in the art, and is not limited by the above-described method.

According to one aspect of the present invention, in the composition, the composition may include a tea tree root extract in an amount of 0.000001 to 40% by weight based on the total weight of the composition. When the content of the extract was 0.000001 to 40% by weight, the anti-aging and anti-inflammatory effects of the composition including the tea tree root extract were excellent.

Specifically, at least 0.0000001 wt%, at least 0.0000005 wt%, at least 0.0000007 wt%, at least 0.0000009 wt%, at least 0.000001 wt%, at least 0.000002 wt%, at least 0.000004 wt%, at least 0.000006 wt%, at least 0.000008 wt%, at least 0.00001 wt% % or more, 0.00003 wt% or more, 0.00005 wt% or more, 0.00007 wt% or more, 0.00009 wt% or more, 0.0001 wt% or more, 0.0003 wt% or more, 0.0005 wt% or more, 0.0007 wt% or more, 0.0009 wt% or more, 0.001 wt% % or more, 0.01% or more, 0.1% or more, 1% or more, 3% or more, 5% or more, 7% or more, 9% or more, 10% or more, 13% or more, 15% or more % or more, 17% or more, 19% or more, 21% or more, 23% or more, 25% or more, 27% or more, 29% or more, 30% or more, 31% or more, 32% or more % or more, 33 wt% or more, 34 wt% or more, 35 wt% or more, 36 wt% or more, 37 wt% or more, 38 wt% or more, or 39 wt% or more, and 40 wt% or less, 39 wt% or less , 38 wt% or less, 37 wt% or less, 36 wt% or less, 35 wt% or less, 34 wt% or less, 33 wt% or less, 32 wt% or less, 31 wt% or less, 30 wt% or less, 29 wt% or less , 28 wt% or less, 26 wt% or less, 24 wt% or less, 22 wt% or less, 20 wt% or less, 18 wt% or less, 16 wt% or less, 14 wt% or less, 12 wt% or less, 10 wt% or less , 9 wt% or less, 8 wt% or less, 6 wt% or less, 4 wt% or less, 2 wt% or less, 1 wt% or less, 0.1 wt% or less, 0.09 wt% or less, 0.04 wt% or less, 0.01 wt% or less , 0.006 wt% or less, 0.001 wt% or less, 0.0009 wt% or less, 0.0007 wt% or less, 0.00005 wt% or less, 0.00003 wt% or less, 0.00001 wt% or less, 0.000009 wt% or less, 0.000007 wt% or less, 0.000005 wt% or less, 0.000003 wt% or less, 0.000001 wt% or less, 0.0000009 wt% or less, 0.0000007 wt% or less, 0.0000005 wt% or less, 0.0000003 wt% or less, 0.0000002 wt% or less, 0.0000001 wt% or less, or 0.00000009 wt% or less .

Another aspect of the present invention may include an anti-aging or anti-inflammatory use of the composition of the present invention. Specifically, the composition may be an anti-aging composition comprising a tea tree root extract as an active ingredient, or an anti-inflammatory composition comprising a tea tree root extract as an active ingredient.

In one aspect, the present invention provides a composition for inhibiting inflammation or aging by regulating the expression level of a specific gene in skin cells damaged by inflammation or aging stimulation to a normal level.

In one aspect, the composition may be applied to keratinocytes.

In one aspect, specifically, in the present invention, the gene in the skin cell whose expression level is affected by the stimulation of inflammation or aging may include XDH (NM_000379). Since the XDH (NM_000379) is a gene whose expression level is increased by stimulation of inflammation or aging, it suppresses the expression level of these genes and regulates the expression level to a normal level, thereby suppressing inflammation or aging of skin cells.

In one aspect, genes whose expression level is increased by stimulation of inflammation or aging used in the present invention are presented in [Table 1]. In the table, Name means genebank accession ID of NCBI, Gene Symbol means official gene symbol, and Gene title means gene name.

increase gene Name Gene
Symbol Gene title NM_000379 XDH xanthine dehydrogenase

The expression level of the gene or protein may be analyzed by microarray, PCR, NGS (Nest Generation Sequencing), Western blot, Northern blot, ELISA, radioimmunoassay, radioimmunodiffusion method, tissue immunostaining, immunoprecipitation assay, etc. It can be analyzed using a variety of analytical methods known in the art.

In one aspect of the present invention, the composition may be a cosmetic composition, a pharmaceutical composition, or a health functional food composition.

The cosmetic composition includes, for example, various creams, lotions, various creams, lotions, and cosmetics such as skins and cleansing agents, face washes, soaps, and liquid cosmetics.

In one aspect, the cosmetic to which the composition containing the tea tree root extract of the present invention is added may take the form of a solution, an emulsion, a viscous mixture, or the like.

That is, the cosmetic, which is an aspect of the present invention, is not particularly limited in its formulation, and for example, emulsion, cream, lotion, essence, pack, gel, powder, makeup base, foundation, lotion, ointment, patch, serum, cleansing Formulations such as foam, cleansing cream, cleansing water, body lotion, body cream, body oil, body essence, shampoo, conditioner, body wash, soap, hair dye, spray, and the like may be mentioned.

In the cosmetic composition of each formulation, other ingredients other than the tea tree root extract can be appropriately selected and formulated by those skilled in the art without difficulty depending on the formulation or purpose of use of other cosmetics.

In addition, the cosmetic according to an aspect of the present invention may include a composition selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, sphingolipids, and seaweed extract.

In one aspect, in the cosmetic of the present invention, in addition to the above essential ingredients, other ingredients commonly formulated in cosmetics may be blended as needed.

Other ingredients that may be added include oils and fats, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, UV absorbers, preservatives, disinfectants, antioxidants, plant extracts, pH adjusters, alcohols, colorants, fragrances, A blood circulation promoter, a cooling agent, an anti-inflammatory agent, purified water, etc. are mentioned.

In addition, the mixing|blending component which may be added other than this is not limited to this, Moreover, any said component can be mix|blended within the range which does not impair the objective and effect of this invention.

In one aspect, the pharmaceutical composition comprising the tea tree root extract of the present invention may further include suitable carriers, excipients and diluents commonly used in the preparation of pharmaceutical compositions.

As for the formulation, the pharmaceutical composition containing the tea tree root extract is prepared according to a conventional method, including oral preparations such as tablets, capsules, powders or syrups, or external preparations such as ointments, gels, creams, patches or sprays, etc. It can be formulated and used in any form suitable for pharmaceutical preparations.

In general, it should be understood that the actual dosage of the active ingredient administered by the pharmaceutical composition should be determined in light of several related factors such as the severity of symptoms, the route of administration selected, the age, sex, weight and health status of the subject. In general, the dosage of the active ingredient may be 0.0001 mg/kg/day to 3000 mg/kg/day, for example, 10 mg/kg/day to 500 mg/kg/day.

In the health functional food composition of one aspect of the present invention, the health food is manufactured using nutrients or ingredients (functional raw materials) that are easily deficient in daily meals or have useful functions in the human body, and maintain normal functions of the human body. Or it may mean a food that maintains and improves health through physiological function activation, but is not limited thereto. The health food may be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc., but is not limited thereto and may be manufactured and processed in any form according to the law.

Specifically, the health beverage composition is not particularly limited in other ingredients except for containing the compound as an essential ingredient in the indicated ratio, and may contain various flavoring agents or natural carbohydrates as additional ingredients like a conventional beverage. Examples of natural carbohydrates are conventional sugars such as monosaccharide polysaccharides, cyclodextrins, and the like, and sugar alcohols such as xylitol, sorbitol, erythritol and the like. As flavoring agents other than those described above, natural flavoring agents (taumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used.

In general, it should be understood that the actual dosage of the active ingredient administered by the health functional food composition should be determined in light of several related factors such as the severity of symptoms, the route of administration selected, the age, sex, weight and health status of the subject. . In general, the dosage of the active ingredient may be 0.0001 mg/kg/day to 1000 mg/kg/day, for example, 0.02 mg/kg/day to 6 mg/kg/day.

Hereinafter, the configuration and effect of the present invention will be described in more detail by way of examples. However, these examples are provided for the purpose of illustration only to help the understanding of the present invention, and the scope and scope of the present invention are not limited by the following examples.

[Example 1] Preparation of ethanol extract of tea tree root

After washing and drying the roots of tea tree ( Camellia sinensis L. ) obtained from Jeju Osulloc Ranch with purified water and drying them, 100 g of tea tree root powder obtained by sieving is added to 1 L of 70% ethanol aqueous solution, and extracted by stirring at room temperature for more than 12 hours. Filtered with filter paper twice. The extract thus obtained was concentrated under reduced pressure at 50° C. using a distillation apparatus equipped with a cooling condenser and dried to obtain a 70% ethanol extract of tea tree root (dry weight 21.05 g). The saponin content of the 70% ethanol extract of tea root obtained by the above process was about 55.8% by weight based on the total weight of the extract.

[Example 2] Preparation of butanol fraction of ethanol extract of tea tree root

Dissolve 10 g of the extract obtained in Example 1 in 200 mL of distilled water, put it in a 1 L separatory funnel, add 200 mL of butanol, shake well, mix well, and when completely separated into two layers, the upper layer (butanol layer) was taken. The lower layer (water layer) is extracted by repeating the above process twice more using a separatory funnel. The upper layers separated in each extraction process were combined, concentrated under reduced pressure at 50° C. using a distillation apparatus equipped with a cooling condenser, and dried to obtain a butanol fraction (dry weight 4.83 g) of the ethanol extract of tea tree root. The saponin content of the butanol fraction of the ethanol extract of tea tree root obtained by the above process was about 67.6% by weight based on the total weight of the extract.

[Example 3] Preparation of aging and anti-inflammatory stimulants

A low-volume air sampler (Sensidyne, Gillian, Low Volume Air Sampler, FL, U.S.A.) was used to collect fine dust, which is an aging and anti-inflammatory stimulant, and the filter pack was replaced by replacing the filter and denuder around 10 am on every measurement day. Samples were taken for about 24 hours. Every day, fine dust was collected in the Punghae area of Seoul (located in Cheoin-gu, Yongin-si, Gyeonggi-do, on the 6th floor of the dormitory building, Hankuk University of Foreign Studies, Yongin-si, Gyeonggi-do) for 28 days. time was recorded. The sampling flow rate was 16.7L/min, and the flow rate was measured with a flow meter (Model 4143, TSI Inc.) at the start of the measurement, and the flow rate was measured again when the measurement was finished. Teflon filters in the filter pack were weighed before and after sample collection. After weighing the Teflon filter in a desiccator (NIKKO, Japan) with a relative humidity of 40% for 24 hours, the weight was measured twice on an electronic scale (DVG215CD, Ohaus) that displays 5 decimal places and the average value was calculated. recorded. After the sample was collected, the weight was measured twice in a desiccator before measuring the weight, and then the weight was measured twice, and the mass concentration was calculated by comparing it with the weight measured before collection. Extraction of fine dust was carried out by soaking the Teflon filter in 1 mL of ethanol, adding 14 mL of DW, closing the lid with the aerosol collecting surface of the filter in contact with the water surface, and applying ultrasonic waves for 30 minutes with an ultrasonic cleaner. In order to minimize the error caused by moisture in the filtration step, after completely removing the moisture from the filter in a decicator for 48 hours, weigh the filter using an ultra-precision scale (Mettler Toledo Company) that can measure up to 0.1 mg. Weighed and weighed before and after extraction of the filter.

[Example 4] Culture of (normal human) keratinocyte line

(Normal) Human normal epidermal keratinocytes were purchased from Lonza, Inc. (Walkersville, MD, USA) and subcultured in a CO2 incubator at 37°C and 5% CO2 condition. cultured. The cell culture medium was according to Lonza's instructions. KGM-2 Bullet kit CC-4152 (KGM TM-2 Bullet kit, CC-4152) (ingredient: Bovine pituitary extract (BPE)), human epidermal growth in 500 ml of KBM-2 (KBMTM-2, CC-3103) medium Human epidermal growth factor (hEGF), Insulin, Hydrocortisone, Transferrin, Epinephrine, and Gentamycin Suflate + Amphofericin-B (Gentamycin Suflate + Amphofericin-B: GA) -1000)) added KGM-2 Bullet Kit CC-3107 (KGM TM-2 Bullet Kit, CC-3107) was used.

[Example 5] (Normal human) Keratinocyte treatment and cytotoxicity measurement in keratinocytes

In order to confirm the cytotoxicity through treatment with a stimulus, an MTT experiment using a (normal human) keratinocyte line was performed by the method of Mossman et al. (J. Immunol. Methods, 65, 55-63, 1983).

Specifically, a fine dust dispersion was prepared by using a 24-well plate and dispersing the fine dust having a diameter of 2.5 μm obtained by collecting of Example 4 in purified water, and then using the cell culture conditions of Example 5 to prepare a fine dust dispersion of 2.5 × 10 ⁵ Cells cultured under the condition of the number of well cells were treated with the fine dust dispersion and cultured for 24 hours, and then mixed with 5 mg/ml of MTT (3-4,5-dimethylthiazol-2,5-diphenyltetra zolium bromide) to 37 It was further incubated at ℃ for 3 hours. Thereafter, the medium was removed and the formed formazan crystal was dissolved in 500 μl of DMSO. The lysate was transferred to a 96-well plate and aliquoted, and the OD value was measured at an absorbance of 540 nm. The measurement results are shown in FIG. 1 .

As shown in Fig. 1, the concentration (IC20) value showing 80% viability against cytotoxicity by the dispersion in which fine dust of 2.5 micrometers or less is dispersed in the cell line is 12.5 μg / in the case of an aqueous extract of 2.5 micrometers or less. ml.

[Example 6] Confirmation of cell genetic changes in fine dust through Next Generation Sequencing

For RNA-sequence data processing and analysis, reference was made to the general analysis steps developed by Trapnell et al. (2012). RNA-seq data quality was confirmed using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/), and FASTX (http://hannonlab.cshl.edu/fastx_toolkit/) was used. Thus, base and adapter sequences with poor accuracy were removed. Then, alignment was performed using Tophat (Trapnell et al., 2009) and human genome (hg19), and the amount of data of each sample was confirmed using EVER-seq renamed RSeQC (Wang et al., 2012). ). In addition, the expression level of the transcript was quantified using Cufflinks, and the transcription level was compared between the fine dust dispersion treated sample and the normal sample (Trapnell et al., 2010). With an FDR adjusted p-value <0.05, a strict cutoff of ≥2.0 fold-change was applied to determine genes showing a significant difference in expression during treatment of a dispersion of fine dust with a diameter of 2.5 μm. The measurement results are shown in FIG. 2 .

[Example 7] Real-time RT-PCR Quantification

The fine dust having a diameter of 2.5 μm extracted in Example 3 was treated in an amount of 12.5 μg in 1 ml of cell culture medium to human normal keratinocytes cultured in Example 4, and primers of the genes shown in Table 2 (applied biosystems) TaqMan® Primers) was used to measure the relative mRNA expression level. The tea root extract and the butanol fraction prepared in Examples 1 and 2 were used.

increase gene Name Gene
Symbol TaqMan® Primer NM_000379 XDH Hs00166010_m1

The medium was treated with the tea root extract and the butanol fraction at concentrations of 1 ppm and 5 ppm, respectively, and after 24 hours, the culture medium was removed, the cells were washed with 2 ml of Phosphate Buffered Saline (PBS), and then trizol RNA was isolated from cells using a reagent (Trizol reagent, Invitrogen, Carlsbad, CA, USA). The isolated RNA was purified once more with Qiagen's RNA kit (QIAGEN RNeasy kt, QIAGEN, Valencia, CA), and then the Agilent's Bioanalyzer 2100 model instrument (Agilent 2100 BioAnalyzer, Agilent Technologies, Santa Clara, CA, USA) ) was used to confirm the quality of RNA. cDNA was synthesized from the RNA using Invitrogen's Superscript Reverse Transcriptase (RT) kit, Invitrogen, Carlsbad, CA). -RT-PCR: quantitative analysis was performed through real time-reverse transcription polymerase chain reaction). The change in the expression pattern of the gene was evaluated by real-time PCR using the TaqMan gene expression assay kit (TaqMan gene expression assay kit, Applied Biosystems, Foster City, CA) of Applied Biosystems, and the result is [Fig. 2] shown in Both Q-RT-PCR and real-time PCR used were performed according to the standard protocol distributed by Life Technology, and specifically, a process of processing at 95°C for 20 seconds, then processing at 95°C for 3 seconds and at 60°C for 30 seconds. was carried out for 40 cycles.

As shown in [Fig. 2], there is a gene whose expression level increases or decreases in the skin cells stimulated by fine dust, and it can be confirmed that the expression level of the xanthine dehydrogenase (XDH) gene is reduced by the treatment of the tea tree root extract. there was.

Therefore, the tea root extract effectively protects skin cells from damage to skin cells due to inflammation or aging stimulation, and inhibits or prevents the change in the expression level of the above-mentioned specific gene by the inflammation or aging stimulation, thereby providing a normal level of expression level It can be seen that it is possible to have

Hereinafter, formulation examples of the composition according to the present invention will be described, but the cosmetic composition, pharmaceutical composition and health functional food composition can be applied in various formulations, which is not intended to limit the present invention, but only to describe in detail. .

[Formulation Example 1] Tablet

100 mg of tea tree root extract, 400 mg of lactose, 400 mg of corn starch, and 2 mg of magnesium stearate according to the example of the present invention were mixed, and then tableted according to a conventional tablet manufacturing method to prepare tablets.

Ingredients Content (mg) Tea Tree Root Extract 100 lactose 400 corn starch 400 magnesium stearate 2

[Formulation Example 2] Capsules

100 mg of tea tree root extract, 400 mg of lactose, 400 mg of corn starch, and 2 mg of magnesium stearate according to an embodiment of the present invention were mixed, and then filled into gelatin capsules according to a conventional capsule preparation method to prepare capsules.

Ingredients Content (mg) Tea Tree Root Extract 100 lactose 400 corn starch 400 magnesium stearate 2

[Formulation Example 3] Granules

50 mg of tea tree root extract according to an embodiment of the present invention, 250 mg of anhydrous crystalline glucose, and 550 mg of starch were mixed, formed into granules using a fluidized bed granulator, and then filled in a bag.

Ingredients Content (mg) Tea Tree Root Extract 50 anhydrous crystalline glucose 250 starch 550

[Formulation Example 4] Soap

Ingredients content(%) Tea Tree Root Extract 5.00 maintain appropriate amount sodium hydroxide appropriate amount sodium chloride appropriate amount Spices appropriate amount Purified water remaining amount

[Formulation Example 5] Lotion

Ingredients content(%) Tea Tree Root Extract 5.00 L-ascorbic acid-2-magnesium phosphate salt 1.00 Water-soluble collagen (1% aqueous solution) 1.00 sodium citrate 0.10 citric acid 0.05 Licorice Extract 0.20 1,3-butylene glycol 3.00 Purified water remaining amount

[Formulation Example 6] Cream

Ingredients content(%) Tea Tree Root Extract 3.00 Polyethylene glycol monostearate 2.00 Self-emulsifying monostearate glycerin 5.00 cetyl alcohol 4.00 squalene 6.00 Glyceryl 2-ethylhexanoate 6.00 sphingoglycolipids 1.00 1.3-Butylene Glycol 7.00 Purified water remaining amount

[Formulation Example 7] Ointment

Ingredients content(%) Tea Tree Root Extract 5.00 polyvinyl alcohol 13.00 L-ascorbic acid-2-magnesium phosphate salt 1.00 Lauroylhydroxyproline 1.00 Water-soluble collagen (1% aqueous solution) 2.00 1,3-butylene glycol 3.00 ethanol 5.00 Purified water remaining amount

[Formulation Example 8] Preparation of cosmetic solution

Ingredients content(%) Tea Tree Root Extract 3.00 Hydroxyethylene cellulose (2% aqueous solution) 12.00 Xanthan Gum (2% aqueous solution) 2.00 1,3-butylene glycol 6.00 concentrated glycerin 4.00 Sodium hyaluronate (1% aqueous solution) 2.00 Purified water remaining amount

[Formulation Example 9] Health food

compounding ingredients content Tea Tree Root Extract 2mg vitamin A acetate 70μg vitamin E 1.0mg vitamin B1 0.13mg vitamin B2 0.15mg vitamin B6 0.5mg vitamin B12 0.2μg vitamin C 10mg biotin 10 μg nicotinic acid amide 1.7mg folic acid 50 μg Calcium Pantothenate 0.5mg ferrous sulfate 1.75mg zinc oxide 0.82mg magnesium carbonate 25.3mg monobasic potassium phosphate 15mg dicalcium phosphate 55mg Potassium Citrate 90mg calcium carbonate 100mg magnesium chloride 24.8mg

[Formulation Example 10] Health drink

Ingredients content Tea Tree Root Extract 50mg citric acid 1000mg oligosaccharide 100 g Taurine 1 g Purified water remaining amount

Claims (13)

Contains tea tree root extract as an active ingredient,
An anti-aging composition that inhibits the expression of XDH (NM_000379). Contains tea tree root extract as an active ingredient,
An anti-inflammatory composition that inhibits the expression of XDH (NM_000379). 3. The method of claim 1 or 2,
The tea tree root extract is an extract containing saponin, composition. 4. The method of claim 3,
The composition of the tea tree root extract comprising 30 to 70% by weight of saponins based on the total weight of the extract. 3. The method of claim 1 or 2,
The tea tree root extract is one or more selected from the group consisting of water, C ₁ - C ₆ anhydrous or hydrous lower alcohol, acetone, butylene glycol, ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform and hexane. The composition is extracted with a tea extraction solvent and fractionated with a secondary extraction solvent that is anhydrous or hydrous butanol. 6. The method of claim 5,
The composition of claim 1, wherein the tea root extract is first extracted with anhydrous or hydrous ethanol, and secondarily fractionated with anhydrous or hydrous butanol. 3. The method of claim 1 or 2,
The composition, wherein the tea root extract is included in an amount of 0.000001 to 40% by weight based on the total weight of the composition. delete 3. The method according to claim 1 or 2,
The composition is applied to keratinocytes, the composition. 3. The method according to claim 1 or 2,
The composition, wherein the tea tree root extract is administered at a dose of 10 to 500 mg/kg/day. 3. The method of claim 1 or 2,
The composition is a cosmetic composition, composition. 3. The method of claim 2,
The composition is a pharmaceutical composition. 3. The method according to claim 1 or 2,
The composition is a health functional food composition, composition.

Images